Despite encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from PBMs. Such insurers are typically erecting https://gerardwfib529916.prublogger.com/40835225/copyright-s-medication-faces-is-meeting-pbm-hurdles-the-review-of-access-battles